Interactive Financial Charts Not Available

Adma Biologics (ADMA) | Financial Analysis & Statements

Adma Biologics Inc. | Mid-cap | Healthcare

$17.31

-0.75%

Adma Biologics vs Vertex Adma Biologics vs Regeneron Adma Biologics vs BridgeBio Pharma Adma Biologics vs Blueprint Medicines Adma Biologics vs Madrigal Adma Biologics vs S&P 500 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 122.0M

Gross Profit 67.2M 55.11%

Operating Income 42.8M 35.08%

Net Income 34.2M 28.05%

EPS (Diluted) $0.14

Balance Sheet Metrics

Total Assets 510.6M

Total Liabilities 137.2M

Shareholders Equity 373.4M

Debt to Equity 0.37

Cash Flow Metrics

Operating Cash Flow -14.8M

Free Cash Flow -24.4M

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Adma Biologics Income Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Revenue i	426.5M	258.2M	154.1M	80.9M	42.2M
Cost of Goods Sold i	206.9M	169.3M	118.8M	79.8M	61.3M
Gross Profit i	219.6M	88.9M	35.3M	1.2M	-19.1M
Gross Margin % i	51.5%	34.4%	22.9%	1.4%	-45.2%
Operating Expenses
Research & Development i	1.8M	3.3M	3.6M	3.6M	5.9M
Selling, General & Administrative i	74.1M	59.0M	52.5M	42.9M	35.1M
Other Operating Expenses i	4.2M	4.3M	17.8M	12.3M	4.2M
Total Operating Expenses i	80.2M	66.6M	73.9M	58.8M	45.1M
Operating Income i	139.0M	21.6M	-39.4M	-58.4M	-64.9M
Operating Margin % i	32.6%	8.4%	-25.5%	-72.1%	-153.8%
Non-Operating Items
Interest Income i	2.1M	1.6M	45.0K	35.0K	288.1K
Interest Expense i	13.9M	25.0M	19.3M	13.1M	12.0M
Other Non-Operating Income	-1.4M	-26.5M	-7.3M	-252.0K	863.3K
Pre-tax Income i	125.7M	-28.2M	-65.9M	-71.6M	-75.7M
Income Tax i	-72.0M	-	-	-	-
Effective Tax Rate % i	-57.2%	0.0%	0.0%	0.0%	0.0%
Net Income i	197.7M	-28.2M	-65.9M	-71.6M	-75.7M
Net Margin % i	46.4%	-10.9%	-42.8%	-88.5%	-179.4%
Key Metrics
EBITDA i	148.9M	31.3M	-32.8M	-53.1M	-60.8M
EPS (Basic) i	$0.85	$-0.13	$-0.33	$-0.51	$-0.88
EPS (Diluted) i	$0.81	$-0.13	$-0.33	$-0.51	$-0.88
Basic Shares Outstanding i	233084236	223977315	197874895	139578538	86145052
Diluted Shares Outstanding i	233084236	223977315	197874895	139578538	86145052

Income Statement Trend

Adma Biologics Balance Sheet From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Assets
Current Assets
Cash & Equivalents i	103.1M	51.4M	86.5M	51.1M	55.9M
Short-term Investments i	-	-	-	-	-
Accounts Receivable i	50.0M	27.4M	15.5M	28.6M	13.2M
Inventory i	170.2M	172.9M	163.3M	124.7M	81.5M
Other Current Assets	8.0M	5.3M	5.1M	4.3M	3.0M
Total Current Assets i	331.4M	257.0M	270.4M	208.7M	153.7M
Non-Current Assets
Property, Plant & Equipment i	29.9M	30.7M	29.3M	24.0M	18.7M
Goodwill i	7.5M	7.6M	8.1M	8.8M	9.5M
Intangible Assets i	460.0K	499.0K	1.0M	1.7M	2.4M
Long-term Investments	-	-	-	-	-
Other Non-Current Assets	89.9M	4.7M	4.8M	4.1M	-
Total Non-Current Assets i	157.3M	72.2M	78.1M	67.5M	53.9M
Total Assets i	488.7M	329.2M	348.5M	276.3M	207.7M
Liabilities
Current Liabilities
Accounts Payable i	20.2M	15.7M	13.2M	12.4M	11.1M
Short-term Debt i	1.2M	1.0M	905.0K	591.1K	365.7K
Current Portion of Long-term Debt	-	-	-	-	-
Other Current Liabilities	1.9M	2.9M	1.8M	1.0M	207.3K
Total Current Liabilities i	55.5M	49.8M	39.3M	30.4M	19.9M
Non-Current Liabilities
Long-term Debt i	80.9M	140.4M	153.5M	102.3M	97.3M
Deferred Tax Liabilities i	-	-	-	-	-
Other Non-Current Liabilities	1.7M	2.1M	1.8M	397.4K	54.9K
Total Non-Current Liabilities i	84.1M	144.2M	157.2M	104.7M	99.5M
Total Liabilities i	139.7M	194.0M	196.5M	135.1M	119.4M
Equity
Common Stock i	24.0K	23.0K	22.0K	19.6K	10.5K
Retained Earnings i	-308.6M	-506.3M	-478.0M	-412.1M	-340.5M
Treasury Stock i	-	-	-	-	-
Other Equity	-	-	-	-	-
Total Shareholders Equity i	349.0M	135.2M	152.0M	141.2M	88.2M
Key Metrics
Total Debt i	82.1M	141.4M	154.4M	102.9M	97.7M
Working Capital i	275.9M	207.2M	231.1M	178.4M	133.8M

Balance Sheet Composition

Adma Biologics Cash Flow Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income i	197.7M	-28.2M	-65.9M	-71.6M	-75.7M
Depreciation & Amortization i	8.0M	8.3M	7.1M	5.5M	3.9M
Stock-Based Compensation i	13.6M	6.2M	5.2M	3.5M	2.9M
Working Capital Changes i	-16.9M	-18.5M	-25.2M	-57.0M	-36.7M
Operating Cash Flow i	119.0M	-25.9M	-73.5M	-117.9M	-104.0M
Investing Activities
Capital Expenditures i	-8.2M	-4.8M	-13.9M	-13.5M	-12.7M
Acquisitions i	-	-	-	-	-
Investment Purchases i	-	-	-	-	-
Investment Sales i	-	-	-	-	-
Investing Cash Flow i	-8.2M	-4.8M	-13.9M	-13.5M	-12.7M
Financing Activities
Share Repurchases i	-	-	-	-	-
Dividends Paid i	-	-	-	-	-
Debt Issuance i	0	135.0M	151.8M	0	27.5M
Debt Repayment i	-60.0M	-158.6M	-100.0M	-34.0K	-14.0M
Financing Cash Flow i	-65.8M	-40.1M	108.7M	121.0M	143.9M
Free Cash Flow i	110.1M	3.8M	-73.4M	-125.9M	-114.7M
Net Change in Cash i	44.9M	-70.8M	21.3M	-10.3M	27.2M

Cash Flow Trend

Adma Biologics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 19.99

Forward P/E 23.60

Price to Book 10.17

Price to Sales 8.55

PEG Ratio 23.60

Profitability Ratios

Profit Margin 44.06%

Operating Margin 35.09%

Return on Equity 71.23%

Return on Assets 20.81%

Financial Health

Current Ratio 5.33

Debt to Equity 21.04

Beta 0.38

Per Share Data

EPS (TTM) $0.85

Book Value per Share $1.67

Revenue per Share $2.00

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
adma	4.1B	19.99	10.17	71.23%	44.06%	21.04
Vertex	100.7B	27.94	5.86	22.77%	31.86%	8.89
Regeneron	62.9B	14.95	2.06	15.34%	31.37%	9.04
BridgeBio Pharma	9.4B	-16.98	-5.24	36.76%	98.25%	-1.04
Blueprint Medicines	8.4B	-120.99	24.43	-47.71%	-27.70%	208.50
Madrigal	8.5B	-17.67	12.12	-36.30%	-54.68%	17.81

Financial data is updated regularly. All figures are in the company's reporting currency.